Clik here to view.
BriaCell Presents Clinical Data at the 2020 San Antonio Breast Cancer Symposium®
Disease control and survival data is presented from the clinical trials of Bria-IMT alone or in combination with immune checkpoint inhibitors in advanced breast cancer: • Maximum tumor reduction and...
View ArticleClik here to view.
BriaCell Announces Presentation at the 2021 Keystone Symposia Conference:...
• Clinical and pathological data from clinical trial of the Bria-IMT regimen alone or in combination with immune checkpoint inhibitors in advanced breast cancer will be presented at the Keystone...
View ArticleClik here to view.
BriaCell Presents Clinical Data at 2021 Keystone Symposium
Clinical and pathological findings presented from the clinical trials of Bria-IMT alone or in combination with immune checkpoint inhibitors in advanced breast cancer: • Median overall survival of 12.5...
View ArticleBriaCell Announces Pricing of US$25 Million Public Offering and Nasdaq Listing
BERKELEY, Calif. and VANCOUVER, British Columbia, February 23, 2021— BriaCell Therapeutics Corp. (TSX-V:BCT) (NASDAQ: BCTX, BCTXW) (“BriaCell” or the “Company”), a clinical-stage biotechnology company...
View ArticleBriaCell Announces Closing of US$25 Million Public Offering
BERKELEY, Calif. and VANCOUVER, British Columbia, February 26, 2021— BriaCell Therapeutics Corp. (TSX-V:BCT) (NASDAQ: BCTX, BCTXW) (“BriaCell” or the “Company”), a clinical-stage biotechnology company...
View ArticleClik here to view.
BriaCell Therapeutics to Present at the American Association for Cancer...
• Clinical and pathological findings from clinical trial of the Bria-IMT regimen alone and in combination with immune checkpoint inhibitors in advanced breast cancer will be presented at the American...
View ArticleClik here to view.
BriaCell Therapeutics Presents Clinical Data at the American Association for...
Clinical and pathological data presented from the clinical trials of Bria-IMT alone and in combination with immune checkpoint inhibitors in advanced breast cancer indicates high responding subset with...
View ArticleBriaCell Announces Closing of Over-Allotment Option in Connection with U.S....
BERKELEY, Calif. and VANCOUVER, British Columbia, April 12, 2021 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”), a clinical-stage...
View ArticleBriaCell Announces Investor and Media Outreach Programs
BERKELEY, Calif. and VANCOUVER, British Columbia, April 15, 2021— BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company...
View ArticleBriaCell to Participate at Upcoming Conferences and Appoints Senior R&D Director
BERKELEY, Calif. and VANCOUVER, British Columbia, May 11, 2021— BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company...
View Article
